Europe Cancer Targeted Therapy Market Report Outlook (2021–2031)

The Europe Cancer Targeted Therapy Market size is expected to reach US$ 64,506.6 million by 2031 from US$ 28,020.8 million in 2024. The market is estimated to record a CAGR of 12.8 % from 2025 to 2031.

Executive Summary and Europe Cancer Targeted Therapy Market Analysis:

The Europe cancer targeted therapy market is witnessing strong and sustained growth, driven by advanced healthcare infrastructure, widespread adoption of precision medicine, and strong regulatory support for innovative oncology drugs. Europe represents one of the most mature markets for targeted cancer therapies, supported by high penetration of genomic testing, early adoption of biomarker-driven treatment pathways, and robust reimbursement frameworks across major economies such as Germany, France, the UK, Italy, and Spain.

The region benefits from a well-established oncology ecosystem comprising academic research institutes, comprehensive cancer centers, and pharmaceutical innovation hubs. Targeted therapies—particularly monoclonal antibodies, tyrosine kinase inhibitors, and immune checkpoint inhibitors—are widely integrated into standard-of-care protocols for multiple cancer types. National cancer control programs and EU-funded research initiatives have further accelerated access to novel targeted therapies.

Hospitals remain the primary treatment centers for cancer care across Europe, with specialized oncology hospitals and university medical centers playing a pivotal role in therapy initiation and monitoring. Retail and specialty pharmacies are increasingly involved in dispensing oral targeted therapies—particularly tyrosine kinase inhibitors—supported by strong pharmacovigilance and adherence programs.

Competitive dynamics in Europe are characterized by the presence of leading multinational pharmaceutical companies such as Roche, Novartis, AstraZeneca, Pfizer, Sanofi, and Merck, alongside a growing number of biotech firms focused on niche and rare cancer indications. Market competition is driven by pipeline depth, combination therapy strategies, biosimilar entry, and value-based pricing negotiations with national healthcare systems. Overall, Europe represents a high-value, innovation-driven market with steady demand for both established and next-generation cancer-targeted therapies.

Europe Cancer Targeted Therapy Market - Strategic Insights:

Europe Cancer Targeted Therapy Market Segmentation Analysis:

Key segments that contributed to the derivation of the Europe Cancer Targeted Therapy market analysis are therapy type, indication, and distribution channel.

• By therapy type, the cancer targeted therapy market is segmented into monoclonal antibodies, tyrosine kinase inhibitors, immune checkpoint inhibitors, cancer vaccines, gene therapy, and others. The monoclonal antibodies segment dominated the market in 2024.
• Based on indication, the cancer targeted therapy market is segmented into blood cancer, lung cancer, breast cancer, colorectum cancer, prostate cancer, stomach cancer, cervical cancer, liver and intrahepatic bile duct cancer, thyroid cancer, and other indications. The lung cancer segment dominated the market in 2024.
• In terms of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online stores. The hospital pharmacies segment dominated the market in 2024.

Europe Cancer Targeted Therapy Market Drivers and Opportunities:

Genomic Profiling Advances Driving Biomarker Discovery

Europe has been at the forefront of integrating molecular diagnostics into routine oncology practice, supported by national genomic medicine initiatives, EU-funded research programs, and strong collaboration between academia and industry. Technologies such as next-generation sequencing (NGS), whole-genome sequencing, and liquid biopsy are widely adopted across major European cancer centers, enabling precise identification of actionable mutations, including EGFR, ALK, HER2, BRAF, BRCA, and PIK3CA.

The European Medicines Agency (EMA) actively supports biomarker-driven drug approvals and companion diagnostics, accelerating market entry for targeted therapies. Many European countries provide reimbursement for comprehensive genomic testing—particularly for lung, breast, colorectal, and hematological cancers—which has significantly expanded the eligible patient population for targeted treatments. Biomarker discovery has also enhanced clinical trial efficiency, with Europe serving as a key region for multinational precision oncology trials.

Additionally, the use of real-world evidence (RWE), national cancer registries, and pan-European genomic databases has strengthened biomarker validation and post-marketing surveillance. Liquid biopsy adoption for disease monitoring and resistance detection is further increasing therapy duration and improving clinical outcomes. Collectively, these factors continue to drive sustained demand for cancer-targeted therapies across Europe.

Extending Targeted Treatments to Rare Mutation-Based Tumors

The expansion of targeted therapies into rare cancers and genetically defined tumor subtypes represents a significant market opportunity. Europe's strong regulatory framework—combined with incentives such as orphan drug designation, accelerated assessment pathways, and extended market exclusivity—has encouraged pharmaceutical companies to invest in therapies for rare and ultra-rare cancers.

Tumor-agnostic therapies targeting biomarkers such as NTRK fusions, RET alterations, MSI-H/dMMR status, and FGFR mutations have gained increasing traction across Europe. These therapies allow treatment to be guided by genetic alterations rather than tumor origin, expanding clinical applicability across multiple rare cancer types. European oncology guidelines increasingly incorporate molecular profiling for rare tumors, improving diagnosis rates and treatment access.

Innovative clinical trial designs—including basket and umbrella trials—are widely used across European research networks, reducing development timelines and costs for rare cancer therapies. From a payer perspective, targeted therapies for rare cancers often demonstrate strong cost-effectiveness due to improved survival outcomes and reduced toxicity compared to conventional chemotherapy. As precision oncology continues to advance, expanding targeted therapies into rare, mutation-driven cancers is expected to unlock new revenue streams, strengthen oncology pipelines, and reinforce Europe's position as a global leader in innovation.

Europe Cancer Targeted Therapy Market Size and Share Analysis:

The Europe Cancer Targeted Therapy market demonstrates steady growth, with size and share analysis highlighting evolving trends and competitive dynamics among key players. The report further examines subsegments categorized within therapy type, indication, and distribution channel, offering insights into their contribution to overall market performance.

By therapy type, the monoclonal antibodies subsegment dominated the market in 2024, driven by their broad clinical applicability, strong efficacy, and continued expansion into combination regimens with immunotherapies and targeted small molecules.

Based on indication, the lung cancer subsegment dominated the market in 2024, driven by the structured screening programs, early diagnosis, and extensive availability of biomarker-driven treatment options.

By distribution channel, the hospital pharmacies subsegment dominated the market in 2024, driven by the centralized oncology treatment pathways, administration of injectable biologics, and strict regulatory oversight.

Europe Cancer Targeted Therapy Market Report Highlights:

Europe Cancer Targeted Therapy Market Report Coverage and Deliverables:

The "Europe Cancer Targeted Therapy Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:

• Europe Cancer Targeted Therapy market size and forecast at regional and country levels for key market segments covered under the scope
• Europe Cancer Targeted Therapy market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• Europe Cancer Targeted Therapy market analysis covering key trends, regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the Europe Cancer Targeted Therapy market
• Detailed company profiles, including SWOT analysis

Europe Cancer Targeted Therapy Market Geographic Insights:

The geographical scope of the Europe Cancer Targeted Therapy market report is divided into: Belgium, Austria, Finland, Denmark, Greece, Poland, Romania, Russia, Ukraine, the Czech Republic, Slovakia, Bulgaria, Italy, Luxembourg, Germany, Switzerland, France, the Netherlands, Norway, Portugal, Spain, Sweden, and the UK. Germany held the largest share in 2024.

Germany held the largest market share in 2024, supported by high healthcare expenditure, advanced oncology infrastructure, and rapid adoption of innovative therapies. Country-level dynamics vary across Europe. Germany and France benefit from strong reimbursement frameworks and early access programs for novel targeted therapies. The UK emphasizes value-based healthcare, with treatment adoption guided by health technology assessments from NICE. Southern European countries such as Italy and Spain demonstrate growing adoption, supported by improving access to genomic testing and EU-funded oncology initiatives. Eastern European markets are witnessing gradual growth, driven by healthcare modernization and expanding access to oncology drugs through regional partnerships. Across Europe, hospitals and specialized cancer centers remain the dominant end users, while specialty pharmacies play an increasing role in managing oral targeted therapies. The diversity of healthcare systems across Europe highlights the importance of country-specific pricing, reimbursement, and market access strategies.

Europe Cancer Targeted Therapy Market Research Report Guidance:

• The report includes qualitative and quantitative data in the Europe Cancer Targeted Therapy market across therapy type, indication, distribution channel, and geography.
• The report starts with the key takeaways (chapter 2), highlighting key trends and outlook of the Europe Cancer Targeted Therapy market.
• Chapter 3 includes the research methodology of the study.
• Chapter 4 includes ecosystem analysis.
• Chapter 5 highlights the major industry dynamics in the Europe Cancer Targeted Therapy market, including factors that are driving the market, prevailing deterrents, potential opportunities, as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.
• Chapter 6 discusses the Europe Cancer Targeted Therapy market scenario, in terms of historical market revenues, and forecast till the year 2031.
• Chapters 7 to 11 cover Europe Cancer Targeted Therapy market segments by therapy type, indication, distribution channel and geography across Belgium, Austria, Finland, Denmark, Greece, Poland, Romania, Russia, Ukraine, the Czech Republic, Slovakia, Bulgaria, Italy, Luxembourg, Germany, Switzerland, France, the Netherlands, Norway, Portugal, Spain, Sweden, and the UK. They cover the market revenue, forecast, and factors driving the market.
• Chapter 12 describes the competitive analysis along with the heat map analysis for the key players operating in the market.
• Chapter 13 describes the industry landscape analysis. It provides detailed descriptions of business activities such as market initiatives, new developments, mergers, and joint ventures globally, along with a competitive landscape.
• Chapter 14 provides detailed profiles of the major companies operating in the Cancer Targeted Therapy market. Companies have been profiled on the basis of their key facts, business descriptions, products, financial overview, SWOT analysis, and key developments.
• Chapter 15, i.e., the appendix, is inclusive of a brief overview of the company, a list of abbreviations, and a disclaimer.

Europe Cancer Targeted Therapy Market News and Key Development:

The Europe Cancer Targeted Therapy market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the Europe cancer targeted therapy market are:

• In November 2024, AstraZeneca's Tagrisso (osimertinib) received a positive EU regulatory recommendation as a first targeted therapy for adults with unresectable EGFR-mutated non-small cell lung cancer (NSCLC), following strong Phase III LAURA trial results.
• In June 2025, the European Medicines Agency adopted a positive opinion and authorization for Itovebi (inavolisib) targeting adults with PIK3CA-mutated, estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer.

Key Sources Referred:

• World Health Organization (WHO)
• World Heart Federation (WHF)
• Organisation for Economic Cooperation and Development (OECD)
• The World Bank Group
• Worldometer
• The Lancet
• International Bar Association
• International Trade Administration